Arrowhead starts PhI of RNA hep B drug; InSite Vision welcomes positive PhIII data for drug-delivering eye drop;

> Arrowhead began a Phase I trial of its RNAi drug ARC-520 for the treatment of chronic hepatitis B. The company expects to complete the trial in the fourth quarter of 2013. Release

> InSite Vision hailed positive Phase III results of its AzaSite Plus and DexaSite eye drops to treat blepharitis. Release

> Alliqua began a preclinical proof-of-principle study of its experimental hydrogel patch that contains lidocaine, a pain drug the company hopes to develop for the treatment of localized acute pain, including postoperative pain, back pain, sports injuries and arthritis. Release

> Inovio Pharmaceuticals ($INO) found that its electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth for the treatment of critical limb ischemia and other forms of peripheral arterial disease. Release

> Kala Pharmaceuticals will present data relating to the company's mucosal-penetrating particle technology for drug delivery to the front and back of the eye at the Controlled Release Society 2013 Annual Meeting in Honolulu, HI. Release